Literature DB >> 8792034

Work-related disability: results from the American migraine study.

W F Stewart1, R B Lipton, D Simon.   

Abstract

Migraine headache is a highly prevalent, often severely painful and frequently disabling disorder. The indirect costs related to disability greatly exceed the direct cost of medical care. The objective of this paper is to describe work-related disability associated with migraine headache and predictors of disability. In a two-stage survey of the US population, we estimate missed workdays and impairment at work in a sample of 1663 migraine suffers, age 18 years and older. Lost workday equivalents (LWDE) was derived as the sum of actual missed workdays and the product of percentage effectiveness at work and days at work with the most severe headache. Overall, reported actual lost workdays and reduced effectiveness at work contributed approximately equally to total LWDE. A total of 51.1% of females and 38.1% of male migraineurs experienced six or more LWDE per year. This subgroup of migraine sufferers accounted for about 90% of the total LWDE experienced by all respondents. Among women, headache duration was the strongest predictor of LWDE followed by less significant associations with number of symptoms and pain level. Among men, only pain level was significantly associated with LWDE. Among sociodemographic factors, disability was more likely among older (40+) subjects and less likely among individuals with higher education and higher income (females only), even after adjusting for headache features. Health-care interventions may yield the greatest individual benefit (by reducing pain and disability) and the greatest societal benefit (by reducing indirect costs) if they are directed to those who account for the greatest proportion of disability.

Entities:  

Mesh:

Year:  1996        PMID: 8792034     DOI: 10.1046/j.1468-2982.1996.1604231.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  48 in total

1.  Validation of the work and health interview.

Authors:  Walter F Stewart; Judith A Ricci; Carol Leotta; Elsbeth Chee
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 2.  The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research.

Authors:  Wayne N Burton; Stephen H Landy; Kristen E Downs; M Chris Runken
Journal:  Mayo Clin Proc       Date:  2009-05       Impact factor: 7.616

Review 3.  Almotriptan: a review of its use in migraine.

Authors:  Susan J Keam; Karen L Goa; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Migraine in men: fact sheet. A publication to mark European Migraine Day of Action 2014.

Authors:  Paolo Rossi; Giuseppe Nappi
Journal:  Funct Neurol       Date:  2014 Jul-Sep

Review 5.  Headache and Barometric Pressure: a Narrative Review.

Authors:  Kushagra Maini; Nathaniel M Schuster
Journal:  Curr Pain Headache Rep       Date:  2019-11-09

6.  The Impact of Post-Traumatic Stress Disorder on the Burden of Migraine: Results From the National Comorbidity Survey-Replication.

Authors:  Aruna S Rao; Ann I Scher; Rebeca V A Vieira; Kathleen R Merikangas; Andrea L Metti; B Lee Peterlin
Journal:  Headache       Date:  2015-10-16       Impact factor: 5.887

Review 7.  Workplace productivity. A review of the impact of migraine and its treatment.

Authors:  P Stang; R Cady; A Batenhorst; L Hoffman
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

8.  The migraine work and productivity loss questionnaire: concepts and design.

Authors:  D J Lerner; B C Amick; S Malspeis; W H Rogers; N C Santanello; W C Gerth; R B Lipton
Journal:  Qual Life Res       Date:  1999-12       Impact factor: 4.147

9.  Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes.

Authors:  Stephen Landy; Sarah E DeRossett; Alan Rapoport; John Rothrock; Michael H Ames; Susan A McDonald; Steven P Burch
Journal:  MedGenMed       Date:  2007-06-07

Review 10.  Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal.

Authors:  Chaouki K Khoury; James R Couch
Journal:  Drug Des Devel Ther       Date:  2010-02-18       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.